Cynata Therapeutics is forecast to grow earnings and revenue by 34.1% and 70.4% per annum respectively while EPS is expected to grow by 54.2% per annum.
Key information
34.1%
Earnings growth rate
54.2%
EPS growth rate
Biotechs earnings growth
15.3%
Revenue growth rate
70.4%
Future return on equity
n/a
Analyst coverage
Low
Last updated
05 Aug 2024
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
CHIA:CYP - Analysts future estimates and past financials data (AUD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
6/30/2026
7
-5
-4
-4
1
6/30/2025
1
-8
-8
-8
1
6/30/2024
2
-10
-10
-10
N/A
3/31/2024
2
-12
-11
-11
N/A
12/31/2023
2
-14
-12
-12
N/A
9/30/2023
2
-14
-13
-13
N/A
6/30/2023
2
-14
-14
-14
N/A
3/31/2023
2
-12
-12
-12
N/A
12/31/2022
3
-9
-10
-10
N/A
9/30/2022
5
-7
-7
-7
N/A
6/30/2022
8
-5
-3
-3
N/A
3/31/2022
8
-5
-2
-2
N/A
12/31/2021
8
-4
-1
-1
N/A
9/30/2021
5
-6
-3
-3
N/A
6/30/2021
2
-8
-5
-5
N/A
3/31/2021
2
-7
-5
-5
N/A
12/31/2020
3
-6
-5
-5
N/A
9/30/2020
5
-5
-4
-4
N/A
6/30/2020
7
-4
-3
-3
N/A
3/31/2020
6
-6
-5
-5
N/A
12/31/2019
4
-8
-7
-7
N/A
9/30/2019
3
-8
-7
-7
N/A
6/30/2019
1
-8
-7
-7
N/A
3/31/2019
1
-7
-6
-6
N/A
12/31/2018
1
-6
-5
-5
N/A
9/30/2018
1
-5
-4
-4
N/A
6/30/2018
1
-5
-4
-4
N/A
3/31/2018
1
-5
N/A
-4
N/A
12/31/2017
1
-5
N/A
-5
N/A
9/30/2017
2
-5
N/A
-4
N/A
6/30/2017
2
-5
N/A
-4
N/A
3/31/2017
2
-4
N/A
-3
N/A
12/31/2016
2
-3
N/A
-2
N/A
9/30/2016
1
-4
N/A
-3
N/A
6/30/2016
1
-5
N/A
-4
N/A
3/31/2016
1
-5
N/A
-4
N/A
12/31/2015
1
-5
N/A
-4
N/A
9/30/2015
1
-4
N/A
-4
N/A
6/30/2015
0
-4
N/A
-3
N/A
3/31/2015
0
-3
N/A
-2
N/A
12/31/2014
0
-3
N/A
-2
N/A
9/30/2014
0
-3
N/A
-2
N/A
6/30/2014
0
-3
N/A
-2
N/A
3/31/2014
0
-3
N/A
-1
N/A
12/31/2013
0
-2
N/A
-1
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYP's revenue (70.4% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: CYP's revenue (70.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYP's Return on Equity is forecast to be high in 3 years time